Rheumatoid arthritis is not curable with any currently available treatment. No therapy has ever met the most stringent standard for a cure, which would require complete absence of disease activity, no ongoing joint damage, and no need for medication. What modern treatment can achieve, though, is remission, a state where inflammation is suppressed enough that many people live with minimal or no symptoms for extended periods. The distinction between “cured” and “in remission” matters because it shapes how the disease is managed for life.
Why RA Can’t Be Cured Yet
The root cause of rheumatoid arthritis remains unknown. What researchers do know is that the immune system mistakenly attacks the tissue lining the joints, called the synovium. White blood cells flood into the joint space, triggering inflammation that thickens the synovial lining into an aggressive, tumor-like tissue called pannus. This pannus grows into cartilage and bone, gradually eroding them. At the same time, cells that break down bone become overactive, accelerating destruction from both the joint surface and the bone marrow beneath it.
Because the underlying immune malfunction persists even when symptoms are controlled, stopping all medication carries a real risk of the disease returning. The most demanding definition of remission, set by the FDA, requires zero disease activity plus no X-ray evidence of joint damage for six months after all medications have been discontinued. No treatment has ever met that standard. This is fundamentally why RA is classified as incurable: the immune system’s misdirected programming doesn’t reset on its own, and current drugs manage the downstream inflammation rather than correcting the original error.
What Remission Actually Means
Remission in RA doesn’t mean what most people assume. The formal criteria, developed jointly by the American College of Rheumatology and the European Alliance of Associations for Rheumatology, define remission using a set of measurable thresholds. In the simplest version, a patient qualifies if their tender joint count, swollen joint count, patient-reported global assessment, and a blood marker of inflammation are all at or below 1 on their respective scales. An alternative scoring system adds these numbers together and sets a cutoff of 3.3 or below.
These definitions have real limitations. A person can technically have some tender or swollen joints and still meet certain remission criteria. For many people with established, long-standing disease, the more realistic goal is “low disease activity” rather than full remission. That doesn’t mean treatment has failed. It means the disease is being controlled well enough to protect joints and preserve daily function, even if it isn’t completely silent.
Drug-Free Remission Is Possible but Uncommon
Some patients do reach a point where they can stop medication entirely without the disease flaring back. In a prospective study that carefully tapered patients off their disease-modifying drugs, about 48% maintained clinical remission for six months after stopping. That’s an encouraging number, but it also means roughly half of the patients who attempted it saw their disease return. And six months off medication is a far cry from a permanent cure.
This is why rheumatologists typically frame treatment as long-term management. Even patients who achieve remission stay in close contact with their care team, monitoring blood work and joint exams so that any uptick in disease activity can be caught and treated before it causes lasting damage.
Why Early Treatment Changes Everything
There is a well-documented “window of opportunity” in RA, a period early in the disease when aggressive treatment has the best chance of achieving deep remission and preventing irreversible joint erosion. The concept was first described in 1992 as a roughly two-year window, but more recent research narrows the most critical period to the first 12 weeks after symptoms begin. Joint damage from high disease activity can appear within just a few weeks on imaging, so delays matter.
The standard approach is called “treat to target.” Rather than prescribing a single medication and waiting, doctors measure disease activity at regular intervals and adjust treatment until a specific target, ideally remission, is reached and sustained. Only persistent, continuous remission halts joint damage reliably. Any increase in disease activity, even a brief one, can restart the destructive process. Each flare lasting around six weeks has been linked to a 7% increase in cardiovascular risk, on top of the joint damage it causes.
Flares Happen Even in Remission
Living in remission doesn’t mean symptoms disappear entirely or permanently. Flares, periods of increased pain, stiffness, and swelling, can occur even in people whose disease is well controlled. About 79% of self-reported flares are short, lasting fewer than three days, while the rest persist longer. A flare lasting more than 12 weeks is considered a major flare and typically signals the need for a treatment change.
During a flare, physical activity tends to drop by roughly 1,000 steps per day, and longer or more frequent flares are associated with progressive joint damage over time. This is one of the practical realities of RA that separates remission from a true cure: the disease can reassert itself, and staying ahead of it requires ongoing vigilance.
How Diet and Lifestyle Fit In
Anti-inflammatory diets, particularly Mediterranean-style eating patterns rich in fish, olive oil, vegetables, and whole grains, have shown modest effects on RA symptoms in small studies. In one trial, patients following a Mediterranean diet saw their disease activity score drop from 4.4 to 3.9 over the study period, while the control group’s score stayed flat. Another found a similar pattern, with the diet group’s score dropping from 5.4 to 4.5. These are meaningful but modest improvements, not enough to replace medication, but potentially helpful as a complement to it.
The evidence base is still thin. Only a handful of randomized trials have measured formal disease activity scores in response to dietary changes, so it’s difficult to make strong claims. Regular physical activity, stress management, and adequate sleep also play supporting roles in managing inflammation, though none of these substitutes for disease-modifying drugs in controlling RA.
The Life Expectancy Picture
Even with modern treatment, RA is associated with higher mortality than the general population. A national study in Lithuania found that people with RA have a 41% higher risk of death compared to the general population, driven largely by cardiovascular disease and, in some analyses, cancer. A 20-year Australian study found a standardized mortality ratio of 1.49, meaning RA patients were about 49% more likely to die during the study period than expected. These numbers reflect the toll of chronic, low-grade inflammation on the heart and other organs, even when joints feel fine. This is part of why controlling inflammation, not just managing pain, is the central goal of treatment.
Experimental Therapies Pushing Toward a Cure
The closest thing to a potential cure on the horizon involves reprogramming the immune system itself. CAR-T cell therapy, originally developed for blood cancers, has been tested in a small number of RA patients. Immune cells are removed from the patient, engineered to target and destroy the specific B cells driving the autoimmune attack, and infused back. Of ten RA patients treated so far, nine with seropositive disease (meaning they had detectable autoantibodies in their blood) showed remarkable responses: their autoantibody levels dropped to zero, and they achieved drug-free remission. One patient with seronegative RA initially responded but later relapsed.
Ten patients is far too few to draw conclusions about safety or durability, and large clinical trials are still needed. But the fact that autoantibodies were eliminated entirely, not just suppressed, suggests this approach may be targeting the disease at a deeper level than current drugs. Whether that translates into something that could genuinely be called a cure remains an open question.